A week in Japanese tech
Life Sciences
- Eli Lilly is to market new osteoporosis drug for Japan. Eli Lilly Japan has applied to the Health Ministry for permission to market raloxifene HCl for the treatment of osteoporosis in post-menopausal women. Eli Lilly is developing the Japanese market to compensate for the loss in revenues associated with the expiration of its patent on Prozac.
- Takeda Chemical Industries is to overhaul drug RD processes. The top-ranked pharmaceutical manufacturer will establish a new RD centre to consolidate domestic operations, and strengthen its system for coordinating clinical tests conducted in Japan, the U.S. and Europe, according to product.
- Yakult will sell Aventis Pharma adrenal...
